Podcasts about Cameco

In this episode of On The Line, host Matt Gurney is joined by Kent Fellows, Associate Professor of Economics at the University of Calgary's School of Public Policy, for a conversation about game theory, the trade war, and the challenge of getting Canada's economy moving again. Plus, a very special guest with a special announcement. See more on that below.This episode is brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September we're focusing on the "made-in-Canada" part.Federal and provincial governments have made strong investments in the biomanufacturing sector, but Canada's drug development ecosystem has contracted over time, and there is not yet enough domestic demand to fully utilize many of these advanced biomanufacturing facilities. This becomes a sovereignty problem. If our biomanufacturing facilities can't remain in operation, we lose the ability to develop and manufacture homegrown therapies. We wait for therapies developed in other countries to make their way here –– with no control over when that might happen. BioCanRx requires the research projects it funds to work with Canadian facilities whenever possible, which has helped build and sustain networks across Canada –– but there is still a lot of untapped potential. How can we make sure our infrastructure isn't sitting idle? More on that next week. Visit BioCanRx.com to learn more.First, the trade war. Prof. Fellows recently wrote for The Line about what game theory can tell us about the ongoing trade war, and he and Matt dig into the incentives shaping the decisions being made on both sides of the border. The Americans may be behaving rationally if their objective is to maximize their leverage in the short term. But there are costs to that strategy, particularly as other countries begin making long-term decisions based on the assumption that the United States is no longer a reliable economic partner.This episode is also brought to you by the Forest Products Association of Canada. Every budget season brings endless ideas for how Ottawa should spend. But some of the best ways to strengthen Canada's economy don't require a massive price tag.For Canada's forest products sector, real growth starts with dismantling made-in-Canada barriers: cutting regulatory duplication, fixing supply chain bottlenecks, securing predictable, cost-competitive access to fibre, and creating more certainty for investment.We can't control every global challenge facing our industry, but we can remove the barriers created right here at home.Discover how smarter policy drives economic growth at FPAC.ca.Matt and Kent also discuss the upcoming International Investment Summit in Toronto. It's a good idea: Canada badly needs more investment, greater productivity and stronger economic growth. But attracting investors to a summit is one thing. Convincing them that Canada can actually overcome the regulatory, political and structural obstacles that have discouraged investment in the first place is another.This episode is also brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs carry real risk of delays and cost overruns, and we cannot afford to spend years designing a reactor before construction begins. That is why Cameco believes the AP1000 reactor is the right choice for Canada. It is already operating globally and ready now, with 100 percent Canadian ownership and strong participation from Canadian suppliers. The AP1000 reactor means job creation and supplier contracts, energy security at home, and significant investment staying right here in Canada.A proven design, built on time and on budget. That is how we build Canada. Learn more at ap1000.cameco.com.Then, a special announcement: The Line is growing.Alan Findlay has joined The Line as a reporter and as the first recipient of our Build Canada Fellowship. Over the next year, Alan will be doing fact-based, straight-up investigative reporting into the policy obstacles that are hobbling Canadian productivity and economic growth — digging into what isn't working, why it isn't working, and what could be done differently.And he's hitting the ground running. Alan will be at the prime minister's investment summit in Toronto this week, reporting on what the government is proposing, what investors are saying, and whether Canada is actually prepared to make the changes required to become a more competitive place to invest, build and grow.The Line is excited to have him aboard — and we're looking forward to showing you what he finds. You can read more about the fellowship here. Please join us in welcoming the newest member of the team. And as always, like and subscribe at ReadTheLine.ca.#OnTheLine #CanadaPolitics #TradeWar #CanadaUS #GameTheory #KentFellows #CanadianEconomy #Productivity #Investment #BuildCanada #AlanFindlay #MattGurney

In the latest episode of The Line Podcast, recorded on September 11th, 2026, Matt Gurney and Jen Gerson begin by marking the 25th anniversary of the 9/11 terrorist attacks. They reflect on how profoundly America changed after that morning, how the world changed with it, and how the media environment has transformed in the quarter-century since. They also consider how an attack on that scale would be covered today. Their conclusion? Worse. Much worse.This episode is brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs carry real risk of delays and cost overruns, and we cannot afford to spend years designing a reactor before construction begins. That is why Cameco believes the AP1000 reactor is the right choice for Canada. It is already operating globally and ready now, with 100 percent Canadian ownership and strong participation from Canadian suppliers. The AP1000 reactor means job creation and supplier contracts, energy security at home, and significant investment staying right here in Canada. A proven design, built on time and on budget. That is how we build Canada. Learn more at ap1000.cameco.com.Next, your hosts turn to drones. Canada is partnering with Ukraine as warfare rapidly evolves, and Matt explains why the deal makes a great deal of sense for both countries. Ukraine has extraordinary real-world expertise in drone warfare, while Canada urgently needs to build up its own capabilities. But buying and building drones is the easy part. What exactly is Canada going to do with them? Where will they be stored? How quickly could they be deployed? And under what circumstances might Canada actually use them in, ahem, contingencies? The technology is moving quickly. Canadian defence policy will have to keep up.This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage.Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness' in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how.Find them Fractional-Execs.ca.Finally, Matt and Jen wrap up with a grab bag of looming problems. The Canada–U.S. trade war has become strangely lower-energy on the American side, and they discuss some of the reasons Washington may be increasingly hobbled in pursuing it. Then there's time for a quick tour through the AI apocalypse and the latest on Alberta's referendum.This episode is also brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September we're focusing on the “made-in-Canada” part. Since 2015 BioCanRx has supported the Canadian-Led Immunotherapies Collaborative, or CLIC, in building a truly Canadian pipeline so Canadian patients don't have to wait for cancer therapies developed elsewhere to reach a clinical trial here.In the first iteration, genetic engineering happened in labs in Vancouver, a lab in Ottawa created a viral delivery system, and a facility in Victoria modified each patient's immune cells. The resulting therapy was shipped to a research-intensive hospital where the patient received it. More than 100 patients in B.C., Alberta, Manitoba, and Ontario received treatment. Now the network is growing: new biomanufacturing facilities are preparing to produce cells in Calgary and Ottawa, and new clinical trial sites are being onboarded in other provinces. CLIC technology is being used in three active Canadian clinical trials, with more on the way.So when it comes to producing made-in-Canada cancer immunotherapies, Canada isn't starting from scratch. Thanks to BioCanRx for continuing to help us share these stories. Visit BioCanRx.com to learn more.All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. Like and subscribe.#TheLinePodcast #September11 #CanadaUSRelations #CanadianPolitics #Ukraine #DroneWarfare #CanadianForces #TradeWar #ArtificialIntelligence #AlbertaPolitics

In this episode of On The Line, Jen Gerson speaks with Ronnen Harary, co-founder of Spin Master, the Canadian company behind some of the world's most successful toys and entertainment franchises, including PAW Patrol.This episode is brought to you by BioCanRx. We've been partnering with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September we're focusing on the "made-in-Canada" part. Since 2015 BioCanRx has supported the Canadian-Led Immunotherapies Collaborative, or CLIC, in building a truly Canadian pipeline so Canadian patients don't have to wait for cancer therapies developed elsewhere to reach a clinical trial here. In the first iteration, genetic engineering happened in labs in Vancouver, a lab in Ottawa created a viral delivery system, and a facility in Victoria modified each patient's immune cells. The resulting therapy was shipped to a research-intensive hospital where the patient received it. More than 100 patients in B.C., Alberta, Manitoba, and Ontario received treatment. Now the network is growing: new biomanufacturing facilities are preparing to produce cells in Calgary and Ottawa, and new clinical trial sites are being onboarded in other provinces. CLIC technology is being used in three active Canadian clinical trials, with more on the way. So when it comes to producing made-in-Canada cancer immunotherapies, Canada isn't starting from scratch. Thanks to BioCanRx for continuing to help us share these stories. Visit BioCanRx.com to learn more.Harary takes Jen through the early days of Spin Master and the risks that he and his partners were willing to take while they were still young enough — and perhaps naive enough — to take them. They discuss why your twenties can be an unusually valuable time to take big swings, what entrepreneurs can learn from failure, and why intuition and an understanding of history can matter when trying to distinguish a durable trend from the latest industry bubble.The conversation then widens to Canada's entrepreneurial culture. Harary argues that Canada has enormous creative talent but needs to become more comfortable with ambition, risk and the possibility of failure. He and Jen discuss the difference between building and servicing, the importance of protecting time for deep creative work, and why a successful innovation economy needs diversity not simply of backgrounds, but of ideas, experiences and ways of thinking.This episode is also brought to you by the Forest Products Association of Canada. Every budget season brings endless ideas for how Ottawa should spend. But some of the best ways to strengthen Canada's economy don't require a massive price tag.For Canada's forest products sector, real growth starts with dismantling made-in-Canada barriers: cutting regulatory duplication, fixing supply chain bottlenecks, securing predictable, cost-competitive access to fibre, and creating more certainty for investment.We can't control every global challenge facing our industry, but we can remove the barriers created right here at home.Discover how smarter policy drives economic growth at FPAC.ca.Finally, they look at what Canada could do differently. Harary offers ideas for encouraging entrepreneurship and innovation, attracting and developing talent, and creating a culture in which more Canadians are willing to build companies capable of competing globally.It's a conversation about toys and business, but also about ambition, creativity, risk and what Canada needs to do if it wants to produce more globally successful companies.This episode is also brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs carry real risk of delays and cost overruns, and we cannot afford to spend years designing a reactor before construction begins. That is why Cameco believes the AP1000 reactor is the right choice for Canada. It is already operating globally and ready now, with 100 percent Canadian ownership and strong participation from Canadian suppliers. The AP1000 reactor means job creation and supplier contracts, energy security at home, and significant investment staying right here in Canada. A proven design, built on time and on budget. That is how we build Canada. Learn more at ap1000.cameco.com.As always visit our main page at ReadTheLine.ca, and don't forget to like and subscribe!#OnTheLine #RonnenHarary #SpinMaster #PAWPatrol #Entrepreneurship #CanadianBusiness #Innovation #Canada #Startups #BusinessAdvice #JenGerson

In the latest episode of The Line Podcast, Jen Gerson speaks with Bloomberg senior White House correspondent Josh Wingrove about the collapse of the Canada–U.S. trade deal, the politics behind it, and why Canadians and Americans increasingly seem to be talking past each other.This episode is brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs carry real risk of delays and cost overruns, and we cannot afford to spend years designing a reactor before construction begins. That is why Cameco believes the AP1000 reactor is the right choice for Canada. It is already operating globally and ready now, with 100 percent Canadian ownership and strong participation from Canadian suppliers.The AP1000 reactor means job creation and supplier contracts, energy security at home, and significant investment staying right here in Canada.A proven design, built on time and on budget. That is how we build Canada.Learn more at ap1000.cameco.com.Jen and Josh unpack the breakdown of the latest negotiations, including the competing Canadian and American accounts of what happened and the domestic political pressures shaping both governments. They discuss what Washington actually wants from Canada, how the dispute looks from inside the United States, and what Canadians may be misunderstanding about the political forces driving American policy.This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage. Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness' in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how. Find them Fractional-Execs.ca.They then widen the lens to the broader state of U.S. politics: Donald Trump's hold over the Republican Party, the strength of America's democratic guardrails, the coming midterms, and where the country may be heading politically. Finally, they consider what all of this means for Canada—and for a bilateral relationship that Canadians can no longer take for granted.This episode is also brought to you by BioCanRx. Over the summer we partnered with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September, we want to better understand the “made-in-Canada” part. Many drugs discovered in Canada leave to be developed and commercialized in the United States –– with the benefits accruing there. Completely made-in-Canada immunotherapies are rare because Canada doesn't have a major domestic pharma company to support the development costs or regulatory requirements. BioCanRx is one of the rare not-for-profits with the capacity and expertise to help move Canadian-discovered and manufactured immunotherapies towards the market, both through translational research funding and regulatory support. Promising examples include several therapies now in clinical trials through the Canadian-Led Immunotherapies Collaborative, or CLIC, which are fully designed and manufactured in Canada to target certain blood cancers and, more recently, solid tumours. More on those next time. Visit BioCanRx.com to learn more.All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. Like and subscribe!#TheLinePodcast #CanadaUSRelations #TradeWar #DonaldTrump #MarkCarney #CanadianPolitics #USPolitics #JoshWingrove #USMidterms #CurrentAffairs

In this episode of On The Line, host Matt Gurney is joined by two guests for conversations about political chaos on the west coast and why Canada may need to start thinking very differently about its maritime security.This episode is brought to you by BioCanRx. Over the summer we partnered with federally-funded Canadian not-for-profit BioCanRx to learn how made-in-Canada immunotherapies offer new ways to beat cancer. This September, we want to better understand the "made-in-Canada" part. Many drugs discovered in Canada leave to be developed and commercialized in the United States –– with the benefits accruing there. Completely made-in-Canada immunotherapies are rare because Canada doesn't have a major domestic pharma company to support the development costs or regulatory requirements. BioCanRx is one of the rare not-for-profits with the capacity and expertise to help move Canadian-discovered and manufactured immunotherapies towards the market, both through translational research funding and regulatory support. Promising examples include several therapies now in clinical trials through the Canadian-Led Immunotherapies Collaborative, or CLIC, which are fully designed and manufactured in Canada to target certain blood cancers and, more recently, solid tumours. More on those next time. Visit BioCanRx.com to learn more.First up is Rob Shaw, who has spent more than 18 years covering British Columbia politics and now reports for CHEK News in Victoria. He also hosts the weekly Political Capital podcast and YouTube show, serves as a political correspondent for CBC Radio's All Points West and Radio West, and contributes columns to Business in Vancouver and BC Business Magazine.Rob joins Matt to try to make sense of the unfolding chaos in B.C. politics, where the provincial Conservative Party is in full-on meltdown and Premier David Eby may have an increasingly tempting opportunity to call a snap election and secure a majority as the trade war heats up. The situation is moving so quickly that news was breaking even as Matt and Rob were recording. God only knows what will have happened by the time you hear this. Things are crazy over there.This episode is also brought to you by the Forest Products Association of Canada. Every budget season brings endless ideas for how Ottawa should spend. But some of the best ways to strengthen Canada's economy don't require a massive price tag. For Canada's forest products sector, real growth starts with dismantling made-in-Canada barriers: cutting regulatory duplication, fixing supply chain bottlenecks, securing predictable, cost-competitive access to fibre, and creating more certainty for investment. We can't control every global challenge facing our industry, but we can remove the barriers created right here at home. Discover how smarter policy drives economic growth at FPAC.ca.Then Matt is joined by Jamie Carroll of Carroll and Co. Consulting. Carroll is a former national director of the federal Liberal Party, but this time he's not here to talk politics — at least not initially. Instead, the two discuss Carroll's recent proposal in The Hill Times arguing that Canada needs to grow up, recognize that the rules have changed, and start organizing itself accordingly.His proposal is pragmatic: Canada should find ways to get the Royal Canadian Navy and Canadian Coast Guard working much more closely together. Matt and Jamie discuss how that could strengthen Canada's ability to patrol and defend its enormous maritime approaches, make better use of existing resources, and build national capacity at a time when sovereignty and security are no longer abstract concerns.And then, yes, Matt asks him about the politics of it all.This episode is also brought to you by Cameco. Canada is entering a decisive decade for energy, and the nuclear reactor we choose now matters. Incomplete designs carry real risk of delays and cost overruns, and we cannot afford to spend years designing a reactor before construction begins. That is why Cameco believes the AP1000 reactor is the right choice for Canada. It is already operating globally and ready now, with 100 percent Canadian ownership and strong participation from Canadian suppliers.The AP1000 reactor means job creation and supplier contracts, energy security at home, and significant investment staying right here in Canada.A proven design, built on time and on budget. That is how we build Canada.Learn more at ap1000.cameco.com.Check out our main page at ReadTheLine.ca, like and subscribe, and take good care.#OnTheLine #BCPolitics #BritishColumbia #BCConservatives #DavidEby #RobShaw #CanadaPolitics #CanadianNavy #CanadianCoastGuard #NationalSecurity #JamieCarroll #MattGurney

In the latest episode of The Line Podcast, recorded on August 28th, 2026, Matt Gurney and Jen Gerson begin with the rapidly escalating Canada-U.S. trade war, which somehow managed to get very stupid, very quickly. Ontario Premier Doug Ford told Donald Trump to kiss his ass; Trump responded by signing an executive order renaming Lake Ontario “Lake America.” Your hosts discuss just how weird this confrontation could get—and whether what we're watching now is merely the opening phase of something much longer and more serious.This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.comNext, Matt and Jen argue that Canada still needs to get much better at fighting the communications and information war. The United States has recently confronted Chinese influence operations aimed at shaping its domestic politics, which raises an uncomfortable question: how confident should Canadians be that nobody is trying the same thing here? And if information operations are becoming a normal instrument of state power, should Canada be thinking seriously about developing the capacity to play offence as well as defence?This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementers, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage.Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness' in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how.Find them Fractional-Execs.ca.Finally, your hosts turn to a CBC controversy that sounds considerably crazier in the headlines than it actually is. CBC's longstanding journalistic policy is to avoid independently designating particular acts as “terrorism,” preferring to use the term with attribution—a policy shared in various forms by several major international news organizations. But an internal reminder applying that rule to the 9/11 attacks has predictably exploded into a controversy suggesting that Canada's public broadcaster somehow doesn't believe 9/11 was terrorism. Matt and Jen explain why the underlying policy isn't nearly as stupid as it looks—and also why, in this particular case, it's still dumb enough that CBC should fix it.This episode is also brought to you by BioCanRx. Through our partnership with federally-funded Canadian not-for-profit BioCanRx this summer, we're talking about potential solutions for the problems that are limiting Canada's ability to domestically develop new drugs, especially immunotherapies for cancer. Today: new methods for biomanufacturing.Immunotherapies are created using living components –– sometimes even our own cells — so they're extremely complex and costly to create and deliver to patients. That's why in the United States, only one in five people who could be treated by a personalized therapy like CAR T can afford to receive it. Fortunately, new manufacturing paradigms have the potential to increase accessibility. Similar to how 3D printers can efficiently produce individual mechanical components, closed-system manufacturing creates immunotherapy drugs in self-contained, benchtop machines that enhance efficiency through automation. This turns many hospitals across Canada into potential manufacturing sites and makes scaling up the delivery of personalized therapies to individual Canadian patients a real possibility.Some new manufacturing technologies can even scale from producing a single patient's personalized dose to mass-producing doses for 100,000 patients per day — meaning they could mass-produce vaccines during an emergency.BioCanRx is working with federal partners to understand where this technology can fit within our biomanufacturing regulatory structure, and how AI might help. More on that next time. Learn more at BioCanRx.com.All that and more in the latest episode of The Line Podcast.#TheLinePodcast#CanadaUSRelations#DonaldTrump#DougFord#MarkCarney#TradeWar#ForeignInterference#CBC#CanadianPolitics#CurrentAffairs

In this episode of On The Line, Jen Gerson sits down with Brian Dijkema, president of Cardus Canada, to discuss a new Department of National Defence directive that would move military chaplaincy away from explicit religious language, symbols and prayer in favour of more generic forms of “spiritual reflection.”This episode is brought to you by BioCanRx. Through our partnership with federally-funded Canadian not-for-profit BioCanRx this summer, we're talking about potential solutions for the problems that are limiting Canada's ability to domestically develop new drugs, especially immunotherapies for cancer. Today: new methods for biomanufacturing. Immunotherapies are created using living components –– sometimes even our own cells –– so they're extremely complex and costly to create and deliver to patients. That's why in the United States, only one in five people who could be treated by a personalized therapy like CAR T can afford to receive it. Fortunately, new manufacturing paradigms have the potential to increase accessibility.  Similar to how 3D printers can efficiently produce individual mechanical components, closed-system manufacturing creates immunotherapy drugs in self-contained, benchtop machines that enhance efficiency through automation. This turns many hospitals across Canada into potential manufacturing sites and makes scaling up the delivery of personalized therapies to individual Canadian patients a real possibility.Some new manufacturing technologies can even scale from producing a single patient's personalized dose to mass-producing doses for 100,000 patients per day –– meaning they could mass-produce vaccines during an emergency. BioCanRx is working with federal partners to understand where this technology can fit within our biomanufacturing regulatory structure, and how AI might help. More on that next time. Learn more at BioCanRx.com.Dijkema argues that the change isn't actually neutral. Instead, he sees it as part of a longer-running bureaucratic effort to reduce the visible role of religion within the Canadian Armed Forces. He and Gerson dig into the philosophical question at the heart of the dispute: is secular humanism really a neutral baseline for a diverse society, or is it itself a worldview that the state risks imposing on everyone else? They also talk about what military chaplains actually do. Dijkema argues that chaplains serve a special purpose. Questions about death, war, morality and meaning are not simply clinical problems, and military personnel should have access to people capable of engaging with them through their own religious traditions.This episode is also brought to you by the Forest Products Association of Canada. Canada's resilience will not be built through diversified trade and good intentions alone. It will be built with strong domestic supply chains, reliable Canadian materials, and industries that invest in workers and communities here at home. Two months ago, the federal government acknowledged the Forest Sector Transformation Task Force Report and the practical path it set out. Now the focus must be action. Canada's forest products sector can help deliver the homes, infrastructure, and economic potential the country needs. But that requires predictable access to manage our forests, transportation systems that work, and a regulatory environment that rewards investment rather than delays it. The direction is clear. Now Ottawa needs to turn recognition into results.Learn more at FPAC.ca.Gerson and Dijkema also examine the directive's special treatment of Indigenous spiritual practices, which Dijkema argues is both logically inconsistent and ultimately patronizing. His preferred alternative is straightforward: expand the space available to religious and non-religious Canadians alike rather than trying to make everyone conform to a supposedly neutral middle ground.This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com.Check out our main page at ReadTheLine.ca, and as always, like and subscribe.#OnTheLine #CanadianForces #MilitaryChaplaincy #ReligiousFreedom #Pluralism #BrianDijkema #Cardus #CanadaPolitics #CanadianMilitary #JenGerson

In the latest episode of The Line Podcast, recorded on August 21st, 2026, Matt Gurney joins remotely from Chicago as he makes his way home to Canada after a family event. Sorry, elbows uppers.This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.comThe first segment is, admittedly, a bit of a placeholder. Until there is an actual Canada-U.S. trade deal to read, it's difficult to have firm opinions about it — assuming there even is a deal. Your hosts walk through what's been reported so far and explain why they're reserving judgment until the details are public. That said, Matt highlights one rumoured provision that, if true, would represent a uniquely Canadian style of spectacularly self-inflicted policy failure. For the deeper analysis, look for Sunday's Dispatch.This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementers, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage.Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness' in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how.Find them Fractional-Execs.ca.Next, Matt and Jen examine the early political reaction to both the negotiations themselves and the rumours surrounding the deal. Both were struck by comments this week from Manitoba Premier Wab Kinew. With a combination of clarity and folksy charm, Kinew articulated what your hosts believe is the strongest criticism of Mark Carney's handling of the America file they've heard so far. They're not suggesting Kinew is about to jump into federal politics. He doesn't need to. If someone can make a compelling case that this deal is bad for Canada, Carney could find himself under pressure from both the left and the right.This episode is also brought to you by BioCanRx. Through our partnership with federally-funded Canadian not-for-profit BioCanRx this summer, we're talking about potential solutions for the problems that limit Canada's ability to domestically develop new drugs, especially immunotherapies for cancer.Today: Canada's biomanufacturing capacity. A biomanufacturing industry, like any other industry, does not appear at the swipe of a bureaucrat's pen. Simply allocating money to a new economic development program doesn't replace the years of effort necessary to help a sector put down lasting roots. Canada already has many building blocks in place. For example, infrastructure developed for pandemic readiness after COVID, and money invested in research facilities across Canada, can be leveraged to give us a head start — but they need to be coordinated and given steady work.BioCanRx supports core Canadian biomanufacturing facilities and connects them with active Canadian research projects, making sure both sides have resources and the chance to gain experience. But more activity is needed to ensure these facilities can build up expertise, maintain readiness, and foster innovation. Building this capacity can position Canada to develop new drugs more quickly — and to be ready for a health emergency, all while delivering products to Canadian patients today.There are promising paradigm shifts on the horizon that could change the way we manufacture biologic products like immunotherapies. More on that next week. Visit BioCanRx.com to learn more.Finally, Matt reflects on his recent travels through the United States. There are many ways Canada will never compete directly with America — they're simply bigger and richer. But there are also areas where Canada once had a visible edge and has quietly lost it. Chicago has always had more crime and a higher murder rate than Toronto. That's nothing new. What is new, Matt argues, is that downtown Chicago is now noticeably cleaner and better maintained than downtown Toronto. That's not a consequence of American military power, economic dominance, or Donald Trump. That's a Canadian policy failure. And the really damning part? Downtown Detroit is cleaner than Toronto now, too.All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca. Like and subscribe! #TheLinePodcast#MarkCarney#CanadaUSRelations#TradeDeal#CanadianPolitics#WabKinew#Toronto#Chicago#PoliticalAnalysis#CurrentAffairs

In this episode of On The Line, host Matt Gurney is joined by two guests for conversations about service, sacrifice, and Canada's place in the world.This episode is brought to you by BioCanRx. Through our partnership with federally-funded Canadian not-for-profit BioCanRx this summer, we're talking about potential solutions for the problems that limit Canada's ability to domestically develop new drugs, especially immunotherapies for cancer. Today: Canada's biomanufacturing capacity. A biomanufacturing industry, like any other industry, does not appear at the swipe of a bureaucrat's pen. Simply allocating money to a new economic development program doesn't replace the years of effort necessary to help a sector put down lasting roots. Canada already has many building blocks in place. For example, infrastructure developed for pandemic readiness after COVID, and money invested in research facilities across Canada, can be leveraged to give us a head start –– but they need to be coordinated and given steady work. BioCanRx supports core Canadian biomanufacturing facilities and connects them with active Canadian research projects, making sure both sides have resources and the chance to gain experience. But more activity is needed to ensure these facilities can build up expertise, maintain readiness, and foster innovation. Building this capacity can position Canada to develop new drugs more quickly –– and to be ready for a health emergency, all while delivering products to Canadian patients today. There are promising paradigm shifts on the horizon that could change the way we manufacture biologic products like immunotherapies. More on that next week. Visit BioCanRx.com to learn more.First up is Anthony Robb, a 24-year veteran of the Canadian Army who now serves with Canada Company. He joins Matt to discuss the organization's work strengthening the connection between Canadians and their military, and why that relationship matters more than ever. They also talk about one of Canada Company's most meaningful initiatives: supporting the children of Canadian Armed Forces members who made the ultimate sacrifice in service to their country, and ensuring those families know their sacrifices have not been forgotten. This episode is also brought to you by the Forest Products Association of Canada. Canada's resilience will not be built through diversified trade and good intentions alone. It will be built with strong domestic supply chains, reliable Canadian materials, and industries that invest in workers and communities here at home.Two months ago, the federal government acknowledged the Forest Sector Transformation Task Force Report and the practical path it set out. Now the focus must be action. Canada's forest products sector can help deliver the homes, infrastructure, and economic potential the country needs. But that requires predictable access to manage our forests, transportation systems that work, and a regulatory environment that rewards investment rather than delays it. The direction is clear. Now Ottawa needs to turn recognition into results.Learn more at FPAC.ca.Then Matt is joined by Peter Jones, professor of international relations at the University of Ottawa, for a conversation about one of Canada's most enduring national stories. Canadians often describe their country as a “middle power,” but Jones argues that label hasn't accurately described Canada for quite some time. If we aren't a middle power anymore, what are we? And, more importantly, what should we aspire to be in a world that is becoming less stable, more competitive, and increasingly defined by great-power rivalry? For more on the professor's thoughts on this topic, please read his recent essay in The Walrus.This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com.If you like this — or hey, even if you hated it, we don't mind — check out our main page at ReadTheLine.ca. Be sure to like and subscribe!#OnTheLine #CanadaCompany #CanadianForces #Veterans #AnthonyRobb #PeterJones #ForeignPolicy #CanadaPolitics #NationalSecurity #MattGurney

In the latest episode of The Line Podcast, recorded on August 14th, 2026, Matt Gurney and Jen Gerson begin with a lengthy discussion of the state of the Canada–U.S. trade war. This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.comYour hosts are in complete agreement: Canada should not accept a bad deal. A bad deal wouldn't buy lasting peace, they argue — it would simply set the stage for the next round of American demands. In their view, there is no stable middle ground. Canada either resists now or surrenders now. They also examine the unusual political psychology of the Americans currently running the White House, while cautioning listeners not to expect salvation from the Democrats. A future Democratic administration may be less abrasive, but it won't undo the underlying shift in American policy. As Matt puts it, quoting the late Chris Cornell, "Arm yourselves because no one else here will save you." That includes the likes of Gavin Newsom and Chuck Schumer.This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementers, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage.Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness' in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how.Find them Fractional-Execs.ca.From there, the hosts turn to Alberta and a fascinating Toronto Star investigation tracking the flow of money supporting the separatist movement. The reporting closely matches what both Line editors had already concluded independently. Jen offers an update from the ground in Alberta, while Matt steps back to consider the national implications. Both arrive at the same frustrating conclusion: it would be helpful if Canada's institutions were capable of recognizing foreign interference when it was happening. Recent history suggests we're not only bad at it — we don't even seem particularly interested in trying.Finally, Matt and Jen close with a friendly disagreement over the controversy surrounding Prime Minister Mark Carney's vacation in Italy. They don't see eye to eye, and by the end of the conversation it's clear Matt is unlikely to invite Jen along on his next European vacation. If you'd like to help fund that hypothetical trip, your hosts suggest the usual: like, subscribe, and donate generously.This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit. This summer, BioCanRx and The Line have been talking about potential solutions for the problems that are limiting Canada's ability to domestically develop new drugs, especially immunotherapies for cancer.We ask a lot of Canadian cancer researchers. The work required to discover new therapies for numerous diseases, and get them to patients, costs far more than the half-billion dollars invested in cancer research by all levels of government and charities — and often the available grants specialize in only one part of the spectrum: discovery. We need to be sure we're supporting researchers at every step of this complex scientific and regulatory process.BioCanRx has proved you can meaningfully support this part. The entire team is only 12 people, but they know what it takes to do things like submit a clinical trial application or safely manufacture a drug, so the researchers they fund are held to firm, realistic standards that make sense in the real world of Canadian health-care systems and industry. That's how a tiny not-for-profit has helped bring 16 new drugs to clinical trials that have treated more than 400 people in just 10 years.But research is only one part of the puzzle — can we manufacture new therapies in Canada? More on that next time.Visit BioCanRx.com to learn more.All that and more in the latest episode of The Line Podcast.#TheLinePodcast#MarkCarney#CanadaUSRelations#TradeWar#CanadianPolitics#AlbertaPolitics#ForeignInterference#GavinNewsom#ChuckSchumer#CurrentAffairs

In this episode of On The Line, host Jen Gerson sits down with Jared Wesley and Ken Boessenkool, two members of the Lead Not Leave initiative, for a conversation about the current state of Alberta separatism and the province's uncertain political future.This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit. This summer, BioCanRx and The Line have been talking about potential solutions for the problems that are limiting Canada's ability to domestically develop new drugs, especially immunotherapies for cancer. We ask a lot of Canadian cancer researchers. The work required to discover new therapies for numerous diseases, and get them to patients, costs far more than the half-billion dollars invested in cancer research by all levels of government and charities –– and often the available grants specialize in only one part of the spectrum: discovery. We need to be sure we're supporting researchers at every step of this complex scientific and regulatory process. BioCanRx has proved you can meaningfully support this part. The entire team is only 12 people, but they know what it takes to do things like submit a clinical trial application or safely manufacture a drug, so the researchers they fund are held to firm, realistic standards that make sense in the real world of Canadian health-care systems and industry. That's how a tiny not-for-profit has helped bring 16 new drugs to clinical trials that have treated more than 400 people in just 10 years. But research is only one part of the puzzle — can we manufacture new therapies in Canada? More on that next time. Visit BioCanRx.com to learn more.While recent polling has suggested that support for outright separation may be softer than some headlines imply, neither Wesley nor Boessenkool is particularly sanguine about the outcome of the coming referendum campaign. They argue that low turnout and voter suppression could produce a result that overstates support for separatism, creating a misleading picture of where Albertans actually stand.The discussion also examines the changing relationship between Alberta and Ottawa, and whether recent improvements between the provincial and federal governments have meaningfully reduced the political grievances that have fuelled separatist sentiment. They explore the concept of moral hazard in Canadian federalism, the incentives facing provincial leaders, and whether those dynamics are helping—or hurting—the cause of national unity.This episode is also brought to you by the Forest Products Association of Canada. Canada's resilience will not be built through diversified trade and good intentions alone. It will be built with strong domestic supply chains, reliable Canadian materials, and industries that invest in workers and communities here at home.Two months ago, the federal government acknowledged the Forest Sector Transformation Task Force Report and the practical path it set out. Now the focus must be action. Canada's forest products sector can help deliver the homes, infrastructure, and economic potential the country needs. But that requires predictable access to manage our forests, transportation systems that work, and a regulatory environment that rewards investment rather than delays it. The direction is clear. Now Ottawa needs to turn recognition into results.Learn more at FPAC.ca.Finally, Gerson asks what happens after the vote. Whatever the result, will the United Conservative Party be able to hold together, or are the internal tensions that have defined Alberta conservatism for years becoming too great to contain?As always, check out our main page at ReadTheLine.ca — and never, ever forget to like and subscribe!This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.#OnTheLine #Alberta #AlbertaPolitics #Separatism #LeadNotLeave #JaredWesley #KenBoessenkool #CanadaPolitics #JenGerson #TheLinePodcast

In the latest episode of The Line Podcast, recorded on August 7th, 2026, Matt Gurney is joined by guest host Scott Stinson, filling in for Jen Gerson. They begin with the latest twists in Canada-U.S. relations, asking just how much Prime Minister Mark Carney can concede to the Americans before the political costs become too high at home. Both hosts suspect the answer is probably more than many Canadians would expect. They also discuss how fortunate Carney is to be making these decisions while facing relatively weak opposition, with Pierre Poilievre enduring another difficult week. Matt explains why the Conservative leader continues to struggle to gain traction.This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To larn more, visit ap1000.cameco.com.The conversation then shifts to Ontario politics, where many of the same themes are playing out. It should be a quiet summer at Queen's Park, but instead the Ford government finds itself taking hits from all directions, including from an opposition party that doesn't currently have a permanent leader. Matt and Scott discuss why the Ontario NDP appears so adrift. New Democratic governments are commonplace elsewhere in Canada, so why does the party remain unable to break through in Ontario, even with Doug Ford leading the PCs and the Liberals still searching for direction? Matt has a theory.This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage.Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness' in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how.Find them Fractional-Execs.ca.Finally, Scott brings listeners up to speed on the growing controversy surrounding Gianni Infantino and FIFA. The discussion broadens into a look at why major sports organizations seem almost inevitably to attract corruption—and why it's so fascinating to watch the rare moments when those organizations actually decide to push back.This episode is also brought to you by BioCanRx, a Canadian not-for-profit working to help Canadian researchers and companies develop new drugs, especially immunotherapies for cancer.A key challenge for Canada will be familiar to anyone trying to grow a business here: we have some of the brightest people in the world, we just can't keep enough of them. Canada is home to researchers making breakthrough discoveries every day. But bringing a new therapy from the lab to patients takes more than great science. It also requires specialists who know how to manufacture complex products, navigate regulatory approval, and help new treatments be integrated into the health-care system. Too often, that expertise leaves Canada before the work is done.BioCanRx has supported hands-on training for more than 900 trainees over the past decade, but without a strong domestic industry, retention becomes a challenge. So how do we keep these highly-skilled people? Next time we'll talk about how changing what we incentivize can maximize the impact of research money Canada already spends to sustain more drug development here in Canada. For now, go to BioCanRx.com to learn more.All that and more in the latest episode of The Line Podcast.CHAPTERS00:00 Intro01:37 Can Carney keep conceding? (Yup!)26:39 Fall of Ford48:34 FIFA WTF#TheLinePodcast#MarkCarney#CanadianPolitics#CanadaUSRelations#PierrePoilievre#DougFord#OntarioPolitics#FIFA#GianniInfantino#CurrentAffairs

In this episode of On The Line, host Matt Gurney is joined by two guests for conversations about two of the West's most pressing security challenges: military readiness and cyber defence.This episode is brought to you by BioCanRx, a Canadian not-for-profit working to help Canadian researchers and companies develop new drugs, especially immunotherapies for cancer.A key challenge for Canada will be familiar to anyone trying to grow a business here: we have some of the brightest people in the world, we just can't keep enough of them. Canada is home to researchers making breakthrough discoveries every day. But bringing a new therapy from the lab to patients takes more than great science. It also requires specialists who know how to manufacture complex products, navigate regulatory approval, and help new treatments be integrated into the health-care system. Too often, that expertise leaves Canada before the work is done.BioCanRx has supported hands-on training for more than 900 trainees over the past decade, but without a strong domestic industry, retention becomes a challenge. So how do we keep these highly-skilled people? Next time we'll talk about how changing what we incentivize can maximize the impact of research money Canada already spends to sustain more drug development here in Canada. For now, go to BioCanRx.com to learn more.First up is Mark Cancian of the Center for Strategic and International Studies, a retired U.S. Marine Corps colonel and one of the authors of a new report examining the alarming state of Western ammunition stockpiles. Drawing on the lessons of the wars in Ukraine and the Persian Gulf, Cancian explains how the United States and its allies are consuming critical munitions far faster than they can replace them. The West still possesses enormous military strength, but rebuilding industrial capacity has become an urgent strategic priority. Matt and Mark discuss what's driving the shortages, what governments are finally getting right, and why there are at least a few encouraging signs that production is beginning to catch up.This episode is also brought to you by the Forest Products Association of Canada. Canada's resilience will not be built through diversified trade and good intentions alone. It will be built with strong domestic supply chains, reliable Canadian materials, and industries that invest in workers and communities here at home. Two months ago, the federal government acknowledged the Forest Sector Transformation Task Force Report and the practical path it set out. Now the focus must be action. Canada's forest products sector can help deliver the homes, infrastructure, and economic potential the country needs. But that requires predictable access to manage our forests, transportation systems that work, and a regulatory environment that rewards investment rather than delays it. The direction is clear. Now Ottawa needs to turn recognition into results. Learn more at FPAC.ca.Then Matt is joined by David Shipley of Beauceron Security to discuss a coordinated cyberattack that recently struck a series of public utilities across the United States, causing real disruption to critical infrastructure. They examine who may have been behind the attacks, why utilities remain such attractive targets, and what governments and operators can do to improve their defences. The conversation also turns to whether growing political dysfunction in Washington is making it harder for the United States—and by extension its allies—to respond effectively to increasingly sophisticated cyber threats.It's a pair of conversations about resilience, preparedness, and the growing realization that winning future conflicts will depend as much on industrial capacity and digital security as on military hardware alone.This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com.As always, check out our main page at ReadTheLine.ca, and don't forget to like and subscribe.#OnTheLine #MarkCancian #DavidShipley #CyberSecurity #NationalSecurity #Defense #Military #CSIS #CriticalInfrastructure #MattGurney

Cameco is taking the first steps toward potentially listing its Westinghouse nuclear power subsidiary on the U.S. stock market. Paul Martin, Saskatchewan business commentator and expert, joins Evan to break down what this could mean for Cameco and the nuclear industry.

Steffen Szumowski Nuclear Analyst with Vettafi joined Steve Darling from Proactive to discuss the evolving nuclear energy sector, saying today's industry is "hard to recognize" compared with past decades as restarts, plant life extensions, and new reactor construction replace years of shutdowns. Szumowski said the current nuclear revival began before the recent surge in artificial intelligence, describing AI as "gasoline on top of a fire" rather than the original catalyst. He believes the shift was driven primarily by global climate policies following the Paris Agreement, with growing recognition that renewable energy alone cannot provide the reliable, low-carbon baseload electricity needed to meet future demand. The discussion also focused on energy security, with Szumowski pointing to geopolitical events, including the Russia-Ukraine war and tensions involving Iran, as reinforcing the importance of domestic energy independence. He cited France's large nuclear fleet as an example of how nuclear generation has helped reduce exposure to volatile fossil fuel prices. On reactor development, Szumowski highlighted the rapid pace of new construction in China, ongoing projects in the UK and Russia, and continued progress on advanced reactor technologies in the United States. While no new large-scale reactors have yet broken ground in the U.S., he said companies such as Cameco have suggested additional announcements could emerge through U.S. Department of Energy and Department of Commerce initiatives. Looking ahead, Szumowski believes investors have not missed the opportunity, describing the nuclear renaissance as "still just getting started" with additional announcements expected across both large-scale nuclear plants and small modular reactor projects. One ETF to watch is the Range Nuclear Renaissance Index ETF which is designed to track the performance of companies that are involved in the nuclear fuel and energy. #proactiveinvestors #RangeNuclearRenaissanceIndexETF #NuclearEnergy #NuclearRenaissance #Uranium #EnergyTransition #CleanEnergy #SmallModularReactors #AI #PowerGeneration #Investing #EnergySecurity

Plus: Nuclear company Westinghouse Electric has confidentially filed for an IPO. And New York sues Kalshi, saying the company is running an illegal gambling operation. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In the latest episode of The Line Podcast, recorded on July 31st, 2026, Matt Gurney and Jen Gerson begin by asking whether Canada's governments are actually prepared to make the sacrifices required to defend the country's interests. Both come away disappointed. Matt points to the federal government's decision to block the expansion of an airport in the Toronto area because it was locally controversial and could complicate an upcoming Liberal byelection. If a government isn't willing to risk losing even a single seat to get important things done, Matt argues, then it's never going to get important things done.This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.Next, Jen checks in from Alberta with an update on the separatist movement. While recent polling shows federalist forces comfortably ahead, she's far from reassured. The problem isn't the raw level of support for separation, which remains relatively low. It's the intensity. Separatists are deeply motivated, while federalists may assume victory is inevitable and fail to organize or even show up. If that happens, Jen warns, the result could be much closer than today's polls suggest.This episode is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network dedicated to cutting edge cancer immunotherapy research that they're helping Canadian researchers bring from labs to patients in clinical trials — all in Canada.If a drug is discovered in a Canadian lab, and conducts successful clinical trials in Canada, there's a chance it will be launched in Canada. So how do we get more drugs out of Canadian labs and keep them here? Every year around $500 million is spent on Canadian cancer research, but 70 per cent of that is for early-stage work — discovering whether a therapy can do something in the lab. That leaves limited resources for the complex and often disjointed process of moving Canadian innovations from discovery to a clinical trial and hopefully into the health system.BioCanRx has stepped into the gap. They specialize in “translational research” — the unsexy work that makes for boring press releases, but gets results: 16 Canadian cancer immunotherapy clinical trials in just a decade, treating more than 400 patients.Thanks to this, BioCanRx has first-hand experience with the systemic disconnects that are trapping discoveries in Canadian labs, or sending them out of the country to be developed. They have straightforward ideas about how to fix the problems, and spoiler alert: the answer isn't just “add more money.” Stay tuned to learn more in coming weeks, and visit BioCanRx.com to learn more.Finally, Matt raises reports about Jagmeet Singh's possible next job after politics, and he's unimpressed. Jen offers a different perspective, suggesting that perhaps there's something to be said for a political class that takes care of its own after public service. Your hosts don't reach a firm conclusion — but they lay out both sides and leave it to listeners to decide.All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca.#TheLinePodcast#CanadianPolitics#MarkCarney#AlbertaPolitics#Federalism#JagmeetSingh#LiberalParty#PoliticalAnalysis#CanadaPolitics#CurrentAffairs

For decades, Canada has enjoyed the benefits of NATO while spending comparatively little on its own military. That era may be coming to an end.This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network dedicated to cutting edge cancer immunotherapy research that they're helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.If a drug is discovered in a Canadian lab, and conducts successful clinical trials in Canada, there's a chance it will be launched in Canada. So how do we get more drugs out of Canadian labs and keep them here? Every year around $500 million is spent on Canadian cancer research, but 70 per cent of that is for early-stage work –– discovering whether a therapy can do something in the lab. That leaves limited resources for the complex and often disjointed process of moving Canadian innovations from discovery to a clinical trial and hopefully into the health system.BioCanRx has stepped into the gap. They specialize in "translational research" –– the unsexy work that makes for boring press releases, but gets results: 16 Canadian cancer immunotherapy clinical trials in just a decade, treating more than 400 patients.Thanks to this, BioCanRx has first-hand experience with the systemic disconnects that are trapping discoveries in Canadian labs, or sending them out of the country to be developed. They have straightforward ideas about how to fix the problems, and spoiler alert: the answer isn't just 'add more money." Visit BioCanRx.com to learn more.This week on On The Line, host Jen Gerson is joined by Jean-François Bélanger, Senior Non-Resident Associate Fellow at the NATO Defense College, for a wide-ranging discussion about Canada's long-overdue military buildup and what it means for the future of the Alliance. Bélanger's work focuses on deterrence, nuclear strategy, wargaming, multi-domain operations, and military decision-making, making him well placed to explain the strategic thinking behind today's defence debates.As Ottawa commits to dramatically increasing defence spending, Gerson and Bélanger examine what those promises will actually require. Is Canada genuinely preparing for a more dangerous world, or simply catching up after decades of underinvestment? What capabilities do the Canadian Armed Forces need most urgently, and how should those investments be prioritized?The conversation also explores how NATO has evolved in recent years, how the Alliance has adapted to the return of Donald Trump to the White House, and what Canada's role should be in an increasingly uncertain international environment. They discuss the growing strategic importance of the Arctic, the impact of emerging technologies on military planning, and how the character of warfare is changing.This episode is also brought to you by the Forest Products Association of Canada. Canada's forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action.That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results.The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca.Along the way, Bélanger explains why modern defence planning increasingly relies on forecasting, simulations, and sophisticated wargaming, and why many Canadians misunderstand both NATO's purpose and Canada's obligations within it.It's a timely conversation about deterrence, alliance politics, and the difficult choices Canada faces as it prepares for a less stable world.For more, be sure to check out our main page at ReadTheLine.ca. Like and subscribe  This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.#OnTheLine #NATO #CanadaDefence #CanadianForces #JeanFrancoisBelanger #ArcticSecurity #Geopolitics #MilitaryStrategy #JenGerson #CanadaPolitics

Deuxième partie de notre sélection des 10 actions prometteuses pour le second semestre. Guy Legrand  et Gaële Poncelet analysent le potentiel de Novo Nordisk, Cameco, Campine, IBA, Kinepolis et Xior. Entre valeurs de rattrapage, leaders de long terme et pépites belges méconnues, découvrez les opportunités qui pourraient marquer les prochains mois en Bourse. Vincent Juvyns clôture l'épisode avec une réflexion sur l'épargne des Belges et son rôle dans l'économie. Trends Bourse est une chaîne podcast de Trends-Tendances. Plus d'informations et de conseils pour vos investissements sur www.tendances.be/bourse. Vous désirez recevoir chaque jour des conseils d'investissements dans votre boîte électronique, enregistrez-vous gratuitement sur www.tendances.be/newsletters. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In the latest episode of The Line Podcast, recorded on July 24th, 2026, hosts Matt Gurney and Jen Gerson set out with the ambitious goal of keeping each segment to a specific, fixed time. They do not succeed.This episode is brought to you by BioCanRx, Ia federally-funded Canadian not-for-profit research network dedicated to cutting edge cancer immunotherapy research that they're helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.If a drug is discovered in a Canadian lab, and conducts successful clinical trials in Canada, there's a chance it will be launched in Canada. So how do we get more drugs out of Canadian labs and keep them here? Every year around $500 million is spent on Canadian cancer research, but 70 per cent of that is for early-stage work –– discovering whether a therapy can do something in the lab. That leaves limited resources for the complex and often disjointed process of moving Canadian innovations from discovery to a clinical trial and hopefully into the health system.BioCanRx has stepped into the gap. They specialize in "translational research" –– the unsexy work that makes for boring press releases, but gets results: 16 Canadian cancer immunotherapy clinical trials in just a decade, treating more than 400 patients.Thanks to this, BioCanRx has first-hand experience with the systemic disconnects that are trapping discoveries in Canadian labs, or sending them out of the country to be developed. They have straightforward ideas about how to fix the problems, and spoiler alert: the answer isn't just 'add more money." Stay tuned to learn more in coming weeks, and visit BioCanRx.com to learn more.They begin by unpacking a remarkable week in Canada–U.S. relations. New details about the Gordie Howe Bridge agreement have emerged, and neither host likes what they see. Combined with another round of American tariffs, Jen argues that Prime Minister Mark Carney has committed his first major political fumble. Matt agrees that it's a setback, but also argues that the White House is undermining its own objectives. In an unusual role reversal, Matt even attempts to make the best possible case for Carney's strategy — despite having been the more hawkish voice in recent months. Jen isn't convinced.This episode is also brought to you by the Forest Products Association of Canada. Canada's forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action.That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results.The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca.The conversation then turns inward to Canadian politics. Jen argues that Carney is trying to do too many jobs himself. That observation leads both hosts to an amusing realization: Carney relies on his communications staff so infrequently that neither of them even knew who the key players were. Matt also argues that while the Conservatives remain effective at opposing the government on domestic issues, they're badly missing the mark on foreign affairs, and that's probably because they don't want to admit some things that they'd find awkward and unpleasant. Jen concludes that Canada really needs the Liberals' strategic instincts combined with the Conservatives' tactical effectiveness. Matt predicts, with characteristic optimism, that the country will somehow end up with neither.This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.Finally, Matt ties together many of the themes from the episode by examining the recent arrest of a man alleged to have been involved in terrorism on behalf of Hamas against Canadian Jews. Matt simply walks through the timeline of the investigation and the eventual arrest. The chronology, he argues, speaks for itself. All that and more in the latest episode of The Line Podcast.#TheLinePodcast#MarkCarney#CanadianPolitics#CanadaUSRelations#TradeWar#GordieHoweBridge#PierrePoilievre#NationalSecurity#PoliticalAnalysis#CurrentAffairs

In this episode of On The Line, host Matt Gurney sits down with Reece Martin, transit and transportation expert and new media entrepreneur, for a conversation about infrastructure, public policy, and how an online passion project turned into a career.This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network focused on cutting-edge cancer immunotherapy research that they're helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.  A new treatment for your cancer has been approved. Can you get it? Maybe, maybe not. Canada isn't just one health jurisdiction. At the federal level, Health Canada assesses the safety and efficacy of all drugs and therapies in the country, and in a year — sometimes less — they can approve one for sale in Canada. Once approved, — or sometimes while the assessment is happening— the drug's cost effectiveness is evaluated by Canada's Drug Agency.  Then the ball goes to the provinces. They work together to negotiate prices with the drug maker, to confirm that it doesn't duplicate something they're already stocking, and that its potential value justifies its cost. Only after that can it be provided by each province's ministry of health. This process can take years. It's one reason that Canadian innovations leave the country to be developed elsewhere, and why drug companies don't always choose Canada initially to launch their products. In the U.S., they get FDA approval, set a price, and wait for the market to decide if the price is right. In Canada, Health Canada approves and lengthy negotiations start, with no revenue or guarantee of future approval.Organizations like BioCanRx are willing to wait out the dry years because they're not-for-profit, but companies with shareholders might skip the Canadian market until they're making big money elsewhere. This means Canadians have to wait on the system for drugs that could save them, and are saving people in other countries. We'll talk more about these problems in the weeks to come. Stay tuned for more.Martin explains how his fascination with transit and transportation grew into a successful YouTube channel, and how that work eventually made him a go-to commentator for conventional media on major infrastructure issues. They discuss the opportunities created by the new media landscape, the challenges of building an audience around complex policy topics, and why expertise can now emerge from outside traditional institutions.From there, the conversation turns to Canada's infrastructure record. Matt and Jen often joke that “Canada no build good,” and Martin largely agrees — but with important caveats. He explains where Canada consistently goes wrong, why projects take so long and cost so much, and how political incentives often work against good long-term planning.This episode is also brought to you by the Forest Products Association of Canada. Canada's forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action.That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results.The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca.At the same time, Martin argues that Canada has real infrastructure success stories that deserve more attention. Rather than assuming failure is inevitable, governments should study the jurisdictions that consistently deliver major projects on time and on budget, both at home and abroad. If Canada can learn those lessons — and avoid the kinds of procurement failures that have plagued everything from pipelines to military equipment — our cities could finally get the transit systems they need.And yes, that conversation inevitably leads to the question every Canadian transit enthusiast eventually asks: will Canada actually build true high-speed rail?Be still, our beating hearts. Check out our main page at ReadTheLine.ca, and be sure to check out and follow Reece's YouTube channel and Substack, as well. This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.YOUTUBE: https://www.youtube.com/c/RMTransit/videosSUBSTACK: https://www.thetransitbrief.net/

In this episode of On The Line, host Jen Gerson is joined by Andrew Leach, noted energy and environmental economist and professor of economics and law at the University of Alberta, for a conversation about Canadian energy policy at a pivotal moment.This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada.A drug that can treat your cancer is being tested in a Canadian clinical trial, but can you access it? Depends — where do you live? Clinical trials taking place in Canada usually open sites in major centers with research hospitals. Smaller hospitals face many challenges including having enough know-how to deliver experimental therapies, and administrative, legal, and regulatory responsibilities that come with a trial. There are also data and interoperability issues at hospitals that don't routinely participate in research.So if you don't live in a major centre, participating in the trial requires you to relocate there for the duration of treatment –– the cost of the treatment is covered, but the cost of being in the city where it happens is your responsibility. Patient advocacy groups might be able to help with some of those expenses, but this obviously can be a barrier for a lot of Canadians. A therapy might only become available to everyone across Canada if a trial is successful and the drug is approved –– but not necessarily, and maybe not anytime soon. More on that next time. Visit BioCanRx.com to learn more.Recorded on July 2, 2026, just ahead of two major pipeline announcements, the discussion doesn't cover the specifics of the federal government's decision to retrace the TMX route or the proposed Canadian Shield pipeline between Alberta and Sarnia. Instead, Gerson and Leach focus on the broader forces shaping Canada's energy future.They discuss Prime Minister Mark Carney's latest Forward Guidance video, the influence of the United States on Canadian energy policy and markets, the promise and limitations of carbon capture and storage, and the political significance of the new Memorandum of Understanding between Alberta and Ottawa. Throughout the conversation, Leach offers his perspective on what has changed — and what hasn't — in the relationship between governments, industry, and the public.This episode is also brought to you by the Forest Products Association of Canada. Canada's forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action.That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results.The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca.The episode also asks a larger question: after decades of political conflict over pipelines, is Canada finally entering a new era? Could this be the beginning of a more grounded conversation about the country's oil and gas sector, one that focuses less on symbolic battles and more on practical questions of economics, infrastructure, and national interest?This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.If you enjoyed the episode, be sure to share it, and as always, like and subscribe to us on your podcast or video app of choice. Be sure to check out our main page at ReadTheLine.ca.#OnTheLine #AndrewLeach #Energy #Pipelines #TMX #OilAndGas #MarkCarney #Alberta #CanadaPolitics #JenGerson

The Conservatives have lost another seat in Parliament after Prime Minister Carney appointed Quebec MP Richard Martel to Canada's Senate. Also receiving a seat in the Red Chamber is longtime Liberal strategist, and Carney's current Principle Secretary, Tom Pitfield. Vassy Kapelos is joined alongside Stephanie Levitz, a senior reporter with The Globe And Mail's Ottawa Bureau. On today's show: Vassy speaks with John Bolton, a former U.S. Ambassador and National Security Advisor to President Trump, about this year's NATO Leaders Summit in Turkiye. Hear Vassy's 1-on-1 conversation with Grant Isaac, the CEO of Cameco, about the federal government's nuclear strategy. Money Talk with John Klotz: Canadian vs. American stock markets. The Daily Debrief Panel - featuring Rachel Aiello, Sharan Kaur, and Jamie Ellerton. Vassy goes 1-on-1 with Tjorven Bellmann, Germany's Ambassador to Canada, about Canada's choice to hire German manufacturer TKMS to supply a new fleet of submarines for the Royal Canadian Navy. Sports broadcaster Arash Madani recaps the United States' elimination from the FIFA World Cup, and the controversy over U.S. President Trump calling FIFA's President to overturn a U.S. player's suspension.

In this episode of On The Line, host Matt Gurney sits down with Dr. Brian Goldman, veteran emergency physician at Mount Sinai Hospital in Toronto and author of The Casino Shift: Stories from an ER on the Edge, for a candid conversation about the state of emergency medicine in Canada. (You can find it on Indigo's website, or, if you prefer, on Amazon.)This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada.Clinical trials are the way new drugs, including immunotherapies, are tested in patients around the world. It's up to the developer of the drug to decide whether they want to trial it in Canada –– and many do. Health Canada, our national regulator, reviews and approves all Clinical Trial Applications, or CTAs, returning a decision within 30 days –– a similar turnaround time as the U.S. FDA and other major jurisdictions. If they approve, and if the trial receives research ethics approval, it can start enrolling Canadian patients. To submit a complete CTA, applicants must provide hundreds –– sometimes thousands –– of pages of data showing that a drug has a compelling chance of providing benefit, that it can be manufactured consistently, and that it's safe to administer to trial participants.This is especially hard for Canadian researchers because scientific studies that generate the necessary data aren't supported by many federal grants, which usually prioritize originality over real-world impact. BioCanRx helps Canadian researchers succeed in the CTA process, and so far they've gotten 16 therapies to trial.But once a trial starts, how can Canadians learn about it, and where can they access it? That question and more next time. Visit BioCanRx.com to learn more.Drawing on decades in one of the country's busiest emergency departments, Goldman explains why today's ERs are under extraordinary strain, and why the problems extend far beyond long wait times. They discuss the pressures facing doctors, nurses, and patients alike, the growing mismatch between demand and capacity, and why the old problem of hallway medicine is increasingly giving way to something even worse: chair medicine, with patients waiting for hours in chairs because there simply isn't anywhere else to put them.The conversation also explores the human side of emergency medicine. Goldman reflects on the emotional and psychological toll of working in an overwhelmed system, the stories that inspired The Casino Shift, and what keeps health-care workers coming back despite the mounting pressures.This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry can help build Canada strong. We need more homes, faster and more affordably, and Canadian wood can be part of the solution. Light-frame construction, mass timber, modular systems, and other modern building methods can support housing, lower embodied carbon, and strengthen domestic supply chains. The same opportunity exists in schools, health facilities, community buildings, and public infrastructure. When Canada builds, Canadian materials and Canadian workers must be part of the plan. Learn more at fpac.ca.Finally, Matt and Goldman tackle one of the most contentious questions in Canadian health care. Goldman argues that it's time for a calm, respectful, and evidence-based discussion about whether private options should play a larger role within Canada's publicly funded system. Rather than treating the issue as ideological warfare, he makes the case for focusing on what actually improves patient care, and how other jurisdictions are approaching this problem.It's a frank discussion about the realities facing Canada's healthcare system, the people trying to hold it together, and the difficult choices that may lie ahead.This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.If you enjoyed the episode, be sure to share it, and as always, like and subscribe to us on your podcast or video app of choice, and check out our main page at ReadTheLine.ca.#OnTheLine #BrianGoldman #Healthcare #EmergencyMedicine #CanadianHealthcare #MountSinai #TheCasinoShift #PublicHealth #CanadaPolitics #MattGurney

In today's episode of The Line Podcast, recorded on June 26th, 2026, Matt Gurney and Jen Gerson begin with a rare moment of joy. After decades of delay and political paralysis, there is finally a plan to deal with 24 Sussex Drive. Your hosts don't love every aspect of it, but they're so relieved that someone has finally decided to do something that they're prepared to celebrate. Now comes the hard part: not finding a way to mess it up.This episode of The Line Podcast is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers. To learn more, visit ap1000.cameco.com.From there, they turn to the tragic shooting in Montreal that claimed the life of another police officer. Beyond the immediate heartbreak, your hosts focus on two broader issues. First, they argue that the media should have published the shooter's manifesto. By choosing not to do so, they contend, some early reporting ended up being incomplete or inaccurate. Second, they discuss the rush by commentators across the political spectrum to comb through the manifesto looking for evidence that the attacker perfectly represented their opponents — or, failing that, had nothing whatsoever to do with their own side. Matt and Jen argue that modern terrorism is often ideologically incoherent, and that treating every attack as an opportunity for partisan point-scoring will only make it harder to understand and prevent future violence.This episode is also brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage.Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness' in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how.Find them Fractional-Execs.ca.Finally, Jen makes a wardrobe change that only video viewers will fully appreciate before walking Matt through the increasingly strange politics of the Calgary Stampede. What was once simply Alberta's biggest annual celebration is now becoming another front in an ongoing proxy war between competing factions within the broader conservative movement.This episode is also brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network, which helps bring cutting edge cancer immunotherapy research from Canadian scientists from labs to patients in clinical trials –– all in Canada. Cancer is very good at evading your immune system. But in some tumors, researchers find cancer-killing immune cells called tumour infiltrating lymphocytes, or TILs. They get inside the tumour and start fighting — but they're outnumbered and ill equipped. Researchers in Canada and around the world are studying techniques to extract them from a tumour and multiply them in a lab. Once they number in the millions, they're injected back into the tumour to do more damage. Research into this line of attack against cancer is ongoing. There are plenty of unanswered questions, and we're working hard to answer them. Learn more about this and other critical work at BioCanRx.com.All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca, and as ever, like and subscribe.#TheLinePodcast#CanadianPolitics#24Sussex#Montreal#CalgaryStampede#AlbertaPolitics#PoliticalAnalysis#CanadianMedia#LawEnforcement #CurrentAffairs

Much of the current discussion about nuclear power focuses on advanced technologies, from the potential for nuclear fusion to the development of various designs for small, modular reactors. But if we ask what new nuclear reactors have been built recently in North America and are up and running? The answer is the two reactors at the Vogtle plant in Georgia, which use Westinghouse Electric's AP1000 design. In this episode, Dan Testa interviews Grant Isaac, president and COO of Cameco Corp., a uranium mining and production company that is co-owner of Westinghouse Electric. Isaac says the global nuclear industry is making significant improvements in cost and execution when it comes to building new projects and refurbishing existing reactors – and that the pieces are lining up in the US for utilities to invest in new, large nuclear reactors using Westinghouse's AP1000 design.

Much of the current discussion about nuclear power focuses on advanced technologies, from the potential for nuclear fusion to the development of various designs for small, modular reactors. But if we ask what new nuclear reactors have been built recently in North America and are up and running? The answer is the two reactors at the Vogtle plant in Georgia, which use Westinghouse Electric's AP1000 design. In this episode, Dan Testa interviews Grant Isaac, president and COO of Cameco Corp., a uranium mining and production company that is co-owner of Westinghouse Electric. Isaac says the global nuclear industry is making significant improvements in cost and execution when it comes to building new projects and refurbishing existing reactors – and that the pieces are lining up in the US for utilities to invest in new, large nuclear reactors using Westinghouse's AP1000 design.

In today's episode of On The Line, host Matt Gurney is joined by two guests for conversations about housing, politics, and why governments sometimes struggle to explain themselves.This episode is brought to you by BioCanRx. When your immune system recognizes that cancer is a problem, but can't kill it, can science help? This summer we're partnering with BioCanRx, a federally-funded Canadian not-for-profit research network, to learn about cutting edge cancer immunotherapy research that they're helping Canadian researchers bring from labs to patients in clinical trials –– all in Canada.One of the reasons cancers are so destructive is because they find ways to evade your immune system. But in some tumours, researchers find cancer-killing immune cells called "tumour infiltrating lymphocytes," or TILs. These are like infantry grunts choosing to stand their ground during the final fight in a superhero movie. They get inside the tumour and start fighting – –but they're outnumbered and ill equipped. They need reinforcements.Researchers in Canada and around the world are studying techniques to extract them from a tumour and multiply them in a lab environment. Once they number in the millions, they're sent back into the fight. Research into this line of attack against cancer is ongoing, and there are plenty of questions — we'll be covering more of them over the course of the summer. Go to BioCanRx.com to learn more about these new ways of fighting cancer.First up is Mike Moffatt of the Missing Middle Initiative and co-host of the Missing Middle Podcast. He joins Matt to discuss the much-debated “condo bailout” and why, despite the label, it isn't actually a condo bailout at all. Moffatt argues that the government has done itself no favours by communicating the policy so poorly, and walks listeners through what the plan is — and what it isn't. The conversation then broadens into a look at the state of housing in Canada more generally. There are some signs of progress, but the underlying challenges remain enormous, and Moffatt explains why solving them will require much more than a handful of headline-grabbing announcements.This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry depends on getting goods to market. Forest products move by truck, rail, and ship, and reliability matters. When costs rise or shipments stall, mills, workers, customers, and communities all feel the impact. Stronger trade corridors, better rail performance, labour stability, and reliable transportation should be treated as core parts of Canada's productivity agenda. For a sector rooted in communities and connected to global markets, transportation is transformation. Learn more at FPAC.ca.Then Matt is joined by Andrew MacDougall of Trafalgar Strategy for a look across the Atlantic at the increasingly turbulent state of British politics. They discuss the struggles of now-outgoing Prime Minister Keir Starmer, the rise of Andy Burnham as a potential future national leader, and why so many observers now see the United Kingdom as becoming increasingly difficult to govern. MacDougall argues that the country's problems run deeper than any one politician or party, and offers his own diagnosis of what has gone wrong.It's a pair of conversations about institutions under strain, political communication, and the challenge of governing in an era when public patience is increasingly in short supply.This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.Check out our main page at ReadTheLine.ca, and as always, like and subscribe.#OnTheLine #Housing #MikeMoffatt #MissingMiddle #CanadaHousing #KeirStarmer #AndyBurnham #UKPolitics #AndrewMacDougall #MattGurney

Greenvale has just put its foot on a big lump of land. It says it's highly prospective for uranium in the Northern Territory. It already has extensive known mineralisation and resources, but it believes this is just the start of the game. The exploration program is already underway and Neil Biddle and Alex Cheeseman are wasting no time in pushing the case for their project Guest Bio Neil Biddle is the Executive Chairman of Greenvale Energy Limited and joins The Hole Truth as one of the most experienced figures in Australian hard-rock exploration. A geologist and Corporate Member of the Australasian Institute of Mining and Metallurgy, he has more than 35 years of professional and management experience across precious metals, base metals, iron ore and battery minerals exploration in Australia and overseas. He is best known as a founding director of Pilbara Minerals, where he oversaw the acquisition, drill-out and development of the world-class Pilgangoora lithium project, helping take the company from a small-cap shell to a multi-billion-dollar lithium producer. He was also a founder of Bardoc Gold and the founding managing director of TNG Limited, and now leads Greenvale's push to build a substantial uranium portfolio in the Northern Territory. Alex Cheeseman is the Managing Director of Greenvale Energy Limited and joins The Hole Truth to drive the company's exploration agenda on the ground. A highly experienced Australian resources executive with more than 20 years' experience, he has worked across general management, corporate finance, strategy, commercial, operational and project development roles in the mining, energy and engineering sectors. Appointed Chief Executive Officer in May 2025 and elevated to Managing Director in March 2026, he leads Greenvale's exploration programs across its uranium projects in the Northern Territory and Queensland, as well as the advancement of the Alpha Torbanite project. Produced by Resource Media The Hole Truth: Mining Investment Podcast is a product of Read Corporate. Please note that Read Corporate does not provide investment advice and investors should seek personalised advice before making any investment decisions. Links The Hole Truth LinkedIn: https://www.linkedin.com/showcase/the-hole-truth-podcast The Hole Truth YouTube: https://youtube.com/playlist?list=PLI4sZkSfEpPi_u7OrD7lQ-tZHbdy6EhCC&si=iOcGscff7kMSw8c7 The Hole Truth Website: https://resourcesrisingstars.com.au/the-hole-truth-podcast/ The Hole Truth Instagram: https://www.instagram.com/theholetruthpodcast/ Company Website: https://greenvaleenergy.com.au/ Key Insights A District-Scale Uranium Bet in a Proven Province Greenvale has secured uranium exploration rights over roughly 2,466 square kilometres in the Pine Creek Orogen of the Northern Territory, acquired from Patronus Resources and combined with its adjoining Douglas River ground to form the new Thunderball Uranium Project. Management draws a direct geological analogy to Canada's Athabasca Basin, arguing the southwest portion of the Pine Creek region is highly prospective for unconformity-style uranium yet has been only lightly explored for the past several decades following early discoveries such as Ranger and Jabiluka. Thunderball as the Anchor Deposit and Drilling Focus The package includes the high-grade Thunderball deposit, which carries a historical inferred resource of around 829,000 tonnes at approximately 924 ppm uranium oxide for about 1.7 million pounds of contained uranium under the older JORC 2004 code. Greenvale plans to test extensions at depth and along strike with the aim of releasing an updated, JORC 2012-compliant resource. Cheeseman argues that a conventional hard-rock deposit in the order of 15 to 20 million pounds of high-grade uranium would represent a walk-up mine, framing the existing resource as a starting point rather than the prize. A 20-Kilometre Trend of Repeatable Targets Thunderball sits on the edge of the Hayes Creek fault zone, which management describes as a major mineralising plumbing system running around 20 kilometres into Greenvale's northernmost Douglas River tenement. With recent airborne radiometrics flown over the area, the company expects to define a trend hosting numerous hard-rock and paleochannel calcrete-hosted targets, including a 32-kilometre uranium-rich paleochannel that was drill-ready in 2012. The thesis rests on unconformity-style systems clustering rather than occurring in isolation, given the source granite has been shedding uranium into the system for an estimated 1.2 billion years. A Strengthening Uranium Macro Backdrop Biddle and Cheeseman argue the project is timed to a strengthening uranium cycle, noting that producers such as Cameco and Kazatomprom have signalled they are not incentivised to bring on new capacity until prices reach significantly higher levels than the current spot price. They point to rising long-term price forecasts from analysts, growing nuclear build-out in China, the United States and Europe, and Europe's reclassification of nuclear as green energy as evidence that capital is beginning to flow toward junior uranium explorers after years of underinvestment. Optionality Beyond Uranium: Oasis and Alpha Torbanite Beyond the Northern Territory, Greenvale retains its advanced, high-grade Oasis Uranium Project in Queensland — a roughly 90-square-kilometre uranium anomaly being progressed with geophysics and ground geochemistry ahead of potential drilling next year. The company is also advancing its Alpha Torbanite project, which hosts a 28-million-tonne inferred resource and is positioned to supply Australia's fully imported, roughly billion-dollar bitumen market. With test work progressing through specialist processors toward independent certification, and bitumen prices rising on Middle East supply disruption, the project adds further optionality to the investment case.  

In today's On The Line, host Jen Gerson speaks with Mark Kawar, an amateur historian and journalist whose book America But Bigger explores a surprisingly persistent feature of American history: attempts to expand the United States beyond its current borders.This episode of On The Line is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network helping Canadian researchers bring treatments from labs to patients in clinical trials –– all in Canada. Cancer can hide from your immune system. So how can we target it? Every day, your immune system finds and destroys different types of threats –– both external invaders like viruses, and internal dangers like pre-cancerous cells in your own body. But no system is perfect — sometimes something evades detection. Researchers are working to identify flags found on cancer cells, called antigens. By training your immune system to recognize these antigens as signals for destruction, some forms of immunotherapy equip your immune system to respond to cancer's asymmetrical threat.   In addition to funding clinical trials, BioCanRx supports research teams who identify cancer antigens, and find new ways to target them with immunotherapies. There's still a lot to figure out. Can we train the immune system to hit these antigens before cancer takes root? Why do some cancers still manage to evade therapies designed to find their antigens? Many other questions remain — and we're working on answering them. You'll hear more over the summer. For now, go to BioCanRx.com to learn more.Kawar walks Gerson through the long history of American expansionist ambitions, from schemes that never got off the ground to serious efforts that came much closer to success than many people realize. Along the way, he notes that not every annexation proposal was unwelcome to the people being annexed, and that the historical record is often more complicated than simple stories of American aggression.This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry means investing in the mills and facilities that anchor communities across Canada. Companies are ready to modernize with cleaner equipment, better energy efficiency, advanced wood products, biomaterials, and smarter use of every part of the tree. These are productive, lower-emission, export-oriented investments. But good projects need a workable business case. Our economy needs practical tools to unlock private capital and keep investment here. Learn more at fpac.ca.More importantly, Kawar examines why so many of these projects ultimately failed. The United States has often possessed enormous economic, military, and political power, but translating that power into lasting territorial expansion has proven more difficult than many Americans imagined. Again and again, resistance, geography, politics, and simple practicality imposed limits on what even the world's most powerful country could accomplish.The result is a fascinating conversation about ambition, empire, national identity, and the often-overlooked constraints on American power. It's also a discussion that may hold some lessons for Canadians, should they ever find themselves wondering about the limits of U.S. influence. For whatever reason.This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.Visit our main page at ReadTheLine.ca. Be sure to like and subscribe. We'll be back on Friday with another episode of The Line Podcast.#Canada #Politics #UnitedStates #Greenland #annexation #51 #51State #OnTheLine

In the latest episode of The Line Podcast, recorded on June 12th, 2026, Matt Gurney and Jen Gerson begin with an update from Alberta. Jen reviews Pierre Poilievre's recent speech on why Alberta belongs in Canada. She liked it, with some caveats. Matt was somewhat more encouraged. He also has a few sharp words for Liberals who seem determined to police the boundaries of acceptable federalism. His view is simple: if people are defending Canada, let them defend Canada. Not every argument for national unity needs to come packaged with Liberal talking points. From Toronto, Matt also reflects on a genuine tragedy this week — a police officer killed in the line of duty while confronting a problem that had been allowed to fester for far too long. It's difficult to discuss without emotion. In his view, it never should have ended this way. But, alas, it was always going to: even if the exact tragedy was unforeseen, a tragedy was inevitable. This episode is brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.The hosts then take a very different turn. In what may be the strangest segment of the year, Jen reimagines 250 years of Canada-U.S. relations as a raunchy romantic comedy full of love, betrayal, heartbreak, and, yes, sex. Video viewers can watch Matt become increasingly horrified as the bit unfolds — not because he disagrees with the analysis, but because he finds himself unable to refute it.This episode is also brought to you by BioCanRx, a federally funded, not-for-profit Canadian research network that specializes in bringing Canadian cancer immunotherapy research from the lab all the way to patients in clinical trials in Canada. Immunotherapy is about assisting your immune system in identifying unhealthy cells –– especially cancer –– that have found a way to evade detection. One way researchers are doing this is through something called CAR T. They draw your blood, isolate one type of your immune cells –– T-Cells –– and use a virus to inject genetic instructions that cause them to grow new receptors designed specifically to find and destroy your particular cancer. In one of the 16 trials BioCanRx funds based on Canadian technology, CLIC-01, the median number of months remaining for patients with late-stage leukemia and lymphoma tripled. Some have been cancer free for years.You'll hear more over the summer. For now, go to BioCanRx.com to learn moreAfter that, the hosts wrap up with a discussion about children and social media. Both agree that kids probably shouldn't be spending their lives online. Their concern is that any attempt by the government to solve that problem could easily create several new ones. If recent experience is any guide, they aren't especially confident Ottawa can regulate this area without making a mess of it.All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca, and, as ever, like and subscribe. #TheLinePodcast#PierrePoilievre#AlbertaPolitics#CanadianPolitics#CanadaUSRelations#SocialMedia#Parenting#NationalUnity#PoliticalPodcast#CurrentAffairs

In this episode of On The Line, host Matt Gurney is joined by two guests for conversations about politics, technology, and trust.This episode of On The Line is brought to you by BioCanRX, a federally funded, not-for-profit Canadian research network that specializes in bringing Canadian cancer immunotherapy research from the lab all the way to patients in clinical trials in Canada. Can science help your immune system detect and destroy cancer? Immunotherapy is about assisting your immune system in identifying unhealthy cells –– especially cancer –– that have found a way to evade detection. One way researchers are doing this is through something called CAR T. They draw your blood, isolate one type of your immune cells –– T-Cells –– and use a virus to inject genetic instructions that cause them to grow new receptors designed specifically to bind with your particular cancer. When those cells are re-infused into your body, they hopefully will be able to find and destroy your cancer.  The results are promising. In one of the 16 trials BioCanRx funds based on Canadian technology, CLIC-01, the median number of months remaining for patients with late-stage leukemia and lymphoma tripled. For some, the response was even bigger: they went from being out of options to cancer free, and have stayed that way for several years.Many questions remain — and we're working on answering them. You'll hear more over the summer. For now, go to BioCanRX.com to learn more.First up is PJ Fournier of 338Canada for a look at the latest political numbers. They discuss the good news for Mark Carney, the bad news for Pierre Poilievre, and why the Liberal numbers may not be quite as strong as they first appear. The conversation then turns to Quebec, where the next provincial election is shaping up to be one of the strangest contests either man can remember. Fournier struggles to find a historical comparison. They also discuss softening support for separation in Quebec, how that compares with developments in Alberta, and a point Matt makes that PJ suspects may not be especially popular with Quebec nationalists — even if he doesn't disagree with it.Then Matt is joined by David Shipley of Beauceron Security for a discussion about artificial intelligence, social media, and the growing gap between technological change and political institutions. How much of the current AI boom is real, and how much is hype fuelled by companies racing toward public offerings? Shipley argues that Canadians deserve greater transparency around the Tumbler Ridge case, while Matt notes that he can't even get straightforward answers about transit delays, leaving him less than optimistic about the prospects for accountability.This episode is also brought to you by the Forest Products Association of Canada. A stronger forest industry starts with predictability. Mill modernization, bioenergy, mass timber, and advanced biomaterials all depend on reliable access to usable Canadian wood fibre, workable timelines, and clear rules. Provinces lead forest management, and the federal role should be coordinated, complementary, and focused on results. Every unnecessary delay makes it harder to keep jobs and attract investment. For a sector rooted in communities, regulatory efficiency is economic policy. Learn more at FPAC.ca.The conversation also examines how major social media platforms are being exploited for fraud and manipulation, an issue Shipley has been testifying about. The core problem, he argues, is that the internet moves at the speed of light while politicians move at the speed of Parliament. That mismatch is creating vulnerabilities that are only getting worse. The episode closes with a warning to Albertans heading into a possible referendum campaign: Shipley isn't telling anyone how to vote, but he is urging people to be extremely careful about what they believe online. Foreign interference efforts are already arriving, and they're unlikely to get less sophisticated from here.This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That's why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.To learn more, visit ap1000.cameco.com.Check out our main page at ReadTheLine.ca and be sure to like and subscribe. We'll be back on Friday with another episode of The Line Podcast.#OnTheLine #CanadaPolitics #338Canada #PJFournier #MarkCarney #PierrePoilievre #QuebecPolitics #AlbertaPolitics #ArtificialIntelligence #CyberSecurity #DavidShipley #ForeignInterference #MattGurney

A deep dive into 10 Canadian secondary markets worth serious investor attention in 2026. With Toronto condo sales at a 35-year low and Vancouver projects struggling to hit presale thresholds, capital is flowing into cities where the fundamentals actually pencil.The episode covers Moncton (2.9% population growth, $386K avg price), Halifax (#1 nationally for investor interest, lowest office vacancy in Canada), Quebec City (13% YoY price growth), Ottawa (Ontario's highest industrial rents at $17.33/sq ft, 130K+ federal employees), Hamilton ($2.3B in building permits, LRT in final phases), Kitchener-Waterloo (200K+ tech workers, 46% job growth), Winnipeg (6% multifamily cap rates), Regina (2.9 months of supply, $343K benchmark), Saskatoon (100%+ construction growth, HQ to Nutrien and Cameco), Edmonton (most affordable of Canada's six largest cities), Victoria ($3.15B tech sector), and Kelowna (contrarian buyer's market play).Each market analyzed for population, employers, housing prices, rental data, and the investor thesis. EDMONTON MULTIPLEX EVENT Try it NordVPN risk-free now with a 30-day money-back guarantee! Use our code "realestate" to get 4 extras months from a 2 years plan Exchange-Traded Funds (ETFs) | BMO Global Asset Management LISTEN AD FREESee omnystudio.com/listener for privacy information.

Ongwe Minerals, Cameco, Galantas Gold, Empire Metals, Caledonia Mining, Larvotto Resources, Atlantic Lithium

El analista independiente revisa los títulos de Alphabet, Ciena, Rovi, Infineon o Cameco, entre otros

Scorpio Gold drills 10.40 grams per tonne gold over 5.67 metres. Cameco reported their first quarter financial results. We have corporate updates from Brixton Metals, Snowline Gold, Rua Gold and Gold X2 Mining. This episode of Mining Stock Daily is brought to you by... ⁠⁠Revival Gold ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver⁠⁠⁠⁠Equinox Gold⁠⁠⁠⁠Integra Resources

Grant Isaac, President and COO of Cameco, joins Decouple to explain why uranium behaves unlike any other commodity. With essentially zero fundamental in-year demand, a spot market that reports prices rather than discovering them, and a long-term contracting structure that ties producers directly to the utilities using the fuel, uranium operates by rules that confound anyone who approaches it through the lens of oil, gas, or base metals. Grant walks through Cameco's history as an integrated nuclear fuel company spanning mining, milling, conversion, and now fuel fabrication and reactor services through its Westinghouse partnership, explaining why that vertical integration reflects genuine customer intimacy rather than financial engineering.The conversation covers the full sweep of uranium market cycles from the post-Atoms for Peace inventory buildup through the post-Fukushima bear market, Cameco's decision to curtail 70% of its production rather than sell into a floor, and what is structurally different about the current cycle. The historic secondary supply buffer that held prices down for 30 years is gone, Kazakhstan has learned the lesson that producing more into a weak market destroys national asset value, and geopolitical fragmentation is bifurcating what was once a seamlessly globalized commodity into distinct western and non-western supply chains. Grant argues that the long-term price signal, steady rather than saw-toothing, reflects a more durable demand base than any previous cycle.Listen to Decouple on:• Spotify: https://open.spotify.com/show/6PNr3ml8nEQotWWavE9kQz• Apple Podcasts: https://podcasts.apple.com/us/podcast/decouple/id1516526694?uo=4• Overcast: https://overcast.fm/itunes1516526694/decouple• Pocket Casts: https://pca.st/ehbfrn44• RSS: https://anchor.fm/s/23775178/podcast/rssWebsite: https://www.decouple.media

Keith Bodnarchuk, President and CEO, and Andy Carmichael, VP of Exploration of Cosa Resources Corp. (TSXV: COSA) (OTCQB: COSAF) (FSE: SSKU) , both join me to review the news released on March 24th and today on April 13th which announced anomalous radioactivity in multiple drill holes and completion of the winter 2026 drilling program at the Company's Murphy Lake North Project (MLN).  Both MLN and Darby are joint ventures between Cosa and Denison Mines Corp. (TSX: DML) (NYSE American: DNN) and are located 3kms east of IsoEnergy's Hurricane Deposit, and 10kms west of Cameco's Cigar Lake Mine and respectively, in the eastern Athabasca Basin, Saskatchewan. Cosa is the operator of both projects and holds a 70% interest with Denison holding a 30% interest in each.   Highlights   Radioactivity intersected in three drill holes Radioactivity remains open in multiple directions including for at least 600 metres along strike to the east and 600 metres to the west within the larger kilometre-scale Cyclone alteration zone MLN26-013 intersected 5.0 metres of anomalous radioactivity up to 13,900 CPS1 in the upper basement approximately 260 metres vertically from surface Depth of the radioactivity is shallow at approximately 260 metres vertically from surface Cyclone trend structural corridor is over 100 metres wide and hosts significant alteration consistent with major eastern Athabasca uranium deposits MLN Winter Drilling Approach   Winter drilling at MLN followed up structure and alteration intersected at the Cyclone trend in summer 2025. Five drill holes totaling 2,015 metres were completed during the program with three drill holes intersecting anomalous radioactivity. The first drill hole of the program, MLN26-013, intersected the strongest radioactivity including a 5.0 metre interval of continuously anomalous radioactivity in the upper basement. Two holes were completed to directly follow up radioactivity in MLN26-013. Two additional holes were completed to define underlying geology ahead of summer drilling and follow up another radioactive intersection. All drill holes were completed on Section 3200E.   Drilling determined the Cyclone trend is underlain by a package of graphitic and non-graphitic pelitic gneisses and quartzite over 100 metres in width. The full width of the mineralized structural corridor is unknown as additional prospective graphitic rocks may lie north and south of current drilling.   Next Steps   The Company and its Joint Venture partner, Denison Mines, will be finalizing summer plans in the coming weeks. The drill remains on site for rapid startup when drilling resumes this summer. Assays for all winter drill holes remain outstanding.   If you have any questions for Keith or Andy regarding Cosa Resources then please email them into me at Shad@kereport.com   * In full disclosure, Shad is a shareholder of Cosa Resources at the time of this recording and may choose to buy or sell shares at any time.   Click here to follow the latest news from Cosa Resources   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned, and companies profiled may be sponsors of the KE Report.

The Power Hour is a weekly podcast that discusses the day's most interesting energy and environmental  policy issues with top national experts.  Jack sits down this week for a fascinating discission with long-time Washington policy practitioner and guru Jarrett Blanc.  Jarrett works for one of the world's leading nuclear companies, Cameco, which, alone, is impressive. But […]

The Power Hour is a weekly podcast that discusses the day's most interesting energy and environmental  policy issues with top national experts.  Jack sits down this week for a fascinating discission with long-time Washington policy practitioner and guru Jarrett Blanc.  Jarrett works for one of the world's leading nuclear companies, Cameco, which, alone, is impressive. But what makes his perspective unique is the career that led him to this point.  Jarrett has held senior positions in the Departments of Energy and State, which have taken him to some of the world's most interesting hotspots at some of the most interesting times.   You can learn more about Cameco here.  As always, you can join the conversation at  thepowerhour@heritage.org!  Get Jack's book, Nuclear Revolution, and you can see some of the facilities Jack and Jarrett discussed in our documentary, Powering America.  Thank you for listening and please don't forget to subscribe and help us to spread the word.

Pepe Baynat, Director De Bolsas Y Futuros.com, analiza el momento de las bolsas. El experto financiero asegura que, “estamos en tendencia bajista que empezó con la guerra”, pero aún así ve indicadores positivos y considera que hay señales de fortaleza. “Si entre hoy y mañana se acaba bien habría una señal positiva” dice. En cuanto a valores concretos, Baynat destaca a Cameco, la compañía de uranio. Según el analista “es uno de los valores que vale la pena vigilar”. Ve al valor muy fuerte y considera que cuando tiene correcciones, puede seguir subiendo. Por otro lado, también ha analizado una empresa protagonista esta semana. Puig ha copado los titulares debido a su posible fusión con Estee Lauder. Sobre esta situación, Baynat comenta que la multinacional española de moda y belleza premium “ha querido superar una resistencia pero no ha podido”, sin embargo, apunta que “la fusión puede ser muy positiva para Puig.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Amazon, Disney, Rheinmetall, Wacker Chemie, Atlassian, Bumble, Match Group, Constellation Energy, Energy Fuels, NextEra, Cameco, NexGen Energy, Uranium Energy, Oklo, NuScale, Rolls Royce Holdings, UBS Nuclear Economies UCITS ETF (WKN: A41F41), WisdomTree Uranium and Nuclear Energy UCITS ETF (WKN: A40Y9J), VanEck Uranium and Nuclear Technologies UCITS ETF (WKN: A3D47K), YieldMax Semiconductor Option Income ETF (WKN:A417E0 ), Yieldmax Big Tech Option Income ETF (WKN: A410XV), YieldMax Future of Defence Option Income ETF (WKN: A41SP2), Yieldmax MSTR Option Income Strategy ETC (WKN: A4A5J2), YieldMax ULTY Ultra Option Income Strategy ETC (WKN: A4AQSE). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Alissa Coram and Ed Carson walk through Tuesday's market action and discuss key stocks to watch in Stock Market Today. Learn more about your ad choices. Visit megaphone.fm/adchoices

Interview with Dr. Rebecca Hunter, CEO, Geiger EnergyOur previous interview: https://www.cruxinvestor.com/posts/geiger-energy-tsxvbeep-strategic-merger-positions-dual-basin-uranium-explorer-across-canada-8116Recording date: 4th of March 2026Geiger Energy is positioning itself for potential district-scale uranium discovery in Canada's underexplored Thelon Basin, executing a focused exploration strategy under CEO Dr. Rebecca Hunter's experienced leadership. Following a merger of Forum Energy Metals and Baselode Energy backed by the Ore Group, the company has consolidated its efforts on two flagship projects: the Aberdeen property in the Thelon Basin and the Hook project in Saskatchewan.Dr. Hunter brings significant credibility to the venture, having worked on Cameco's exploration team during the previous uranium boom and examined multiple world-class deposits including McArthur, Cigar, Dawn Lake, and Fox Lake. Her geological expertise centers on recognizing subtle alteration signatures in blind uranium deposits—a critical skill in frontier exploration where deposits lack surface expression.The company is currently deploying its $7 million treasury across both projects. At Hook in Saskatchewan, two drill rigs are operating with a $2.5 million budget, testing for resource expansion near existing mineralization. The flagship Aberdeen program will commence in June with a planned 10,000+ meter drilling campaign focused on the Loki target, where recent drilling intersected intense alteration across the entire sandstone column—similar to signatures seen above world-class Athabasca Basin deposits.Geiger achieved a significant technical milestone by intersecting uranium at the unconformity for the first time in the northeast Thelon Basin. While grades of 100-200 ppm remain sub-economic, this validates the geological model and confirms uranium-bearing hydrothermal systems are present. The next critical step is discovering high-grade mineralization over significant widths, which would fundamentally alter perceptions of the Thelon's potential.The investment thesis rests on first-mover positioning in an underexplored district with geological similarities to the Athabasca Basin, experienced technical leadership, and significant upside leverage. As Dr. Hunter noted, "The big deposits will be found there new ones big ones shallow ones." With sustained newsflow expected throughout 2026 and backing from the Ore Group, Geiger represents exposure to frontier uranium discovery during a favorable macro environment driven by energy security and emerging nuclear demand from AI infrastructure.Learn more: https://www.cruxinvestor.com/companies/geiger-energySign up for Crux Investor: https://cruxinvestor.com

Interview with Chris Frostad, CEO, Purepoint UraniumOur previous interview: https://www.cruxinvestor.com/posts/purepoint-uranium-tsxvptu-6m-premium-raise-isoenergy-backing-boosts-dorado-expansion-8234Recording date: 4th of March 2026Purepoint Uranium has established a distinctive position in uranium exploration through strategic partnerships with industry majors, enabling systematic discovery work across Saskatchewan's Athabasca Basin while minimizing shareholder dilution. The company operates 9-10 projects primarily through joint ventures with Cameco, Orano, and IsoEnergy, earning operator fees while maintaining meaningful equity participation.The partnership model allows Purepoint to deploy significantly more capital than traditional junior explorers. CEO Chris Frostad explained the company can "put $5, $10, $15 million in the ground" while paying only its proportionate share and earning fees for project management. This structure proved critical during uranium's downturn, providing capital continuity when many peers struggled to maintain operations.Purepoint's portfolio includes three principal holdings: 27% of Smart Lake alongside Cameco, 21% of Hook Lake with Cameco and Orano, and a 50-50 partnership with IsoEnergy covering consolidated mine trend properties. The Hook Lake project hosts the Spitfire discovery, a 15-20 million pound deposit that remains below major producer development thresholds but validates the geological potential.Recent success centers on the Nova Discovery at the Dorado project with IsoEnergy. Summer 2025 drilling intersected high-grade mineralisation across four holes testing five-six distinct targets. A 4,500-meter winter program resumed in January 2026, with results expected throughout the year as the company systematically expands understanding of the mineralized system.Capital deployment is accelerating as major partners demonstrate increased urgency. Purepoint expects to deploy approximately $8 million in 2026, potentially doubling to $16 million in 2027. This reflects broader industry dynamics as producers respond to tightening supply fundamentals, highlighted by Cameco's 22 million pound contract to India while western utilities remain passive in securing long-term supply.Frostad characterized the investment opportunity succinctly: "Uranium is not a cycle anymore. This is a get-rich slow thing now, which is fine as part of your portfolio." The methodical, partner-aligned approach prioritizes systematic value creation over headline-driven drilling campaigns.Learn more: https://www.cruxinvestor.com/companies/purepoint-uranium-group-incSign up for Crux Investor: https://cruxinvestor.com

Interview with Philip Williams, CEO, IsoEnergy Ltd.Our previous interview: https://www.cruxinvestor.com/posts/isoenergy-tsxiso-production-advancement-with-exploration-upside-commencing-winter-drill-program-8967Recording date: 1st of March 2026IsoEnergy is a diversified uranium developer and near-term producer operating across Canada, the United States, and Australia — three jurisdictions deliberately chosen for their strong regulatory and mining track records. The company is gaining significant attention from institutional investors as the uranium sector enters what many believe is a sustained structural bull market.Earlier in 2026, IsoEnergy raised $50 million in a capital round that attracted over $300 million in demand — more than six times oversubscribed — from 45 global institutional investors, roughly half of whom were new to the company. CEO Philip Williams, speaking at PDAC 2026, described it as a signal of a meaningful shift: where uranium investing was once the domain of a handful of specialists, generalist funds and large institutions are now actively deploying capital into quality names. IsoEnergy's scale and track record position it to capture that wave.IsoEnergy's flagship asset, the Hurricane deposit in Saskatchewan's Athabasca Basin, holds 48.6 million pounds of U₃O₈ at an average grade of 34.5% — the highest-grade uranium resource on earth. The deposit sits adjacent to Cameco and Orano's Dawn Lake project, whose operators have publicly confirmed high-grade mineralisation comparable to Cigar Lake and McArthur River, the two largest uranium mines in the world. IsoEnergy is currently running an expanded winter drill program and believes significant additional pounds remain to be discovered.The Tony M Mine in Utah is the company's most advanced production asset. A bulk sample program is currently underway underground, generating the data needed for a final restart decision. With approximately $150 million in cash, the company is fully funded for that decision without needing new equity or debt.IsoEnergy stages its portfolio deliberately — advancing Tony M first, then Daneros and Rim in Utah, then its Australian assets — allowing a core technical team to transfer expertise sequentially rather than spreading it thin. This matters because experienced uranium mine builders are globally scarce. The company is also well-positioned to access US government capital, with agencies including the Department of Energy and the Export-Import Bank actively advertising critical minerals funding at industry events.With multiple catalysts converging in 2026 — Hurricane drill results, a Tony M production decision, and broad institutional tailwinds — IsoEnergy is structurally positioned as one of the uranium sector's most compelling development stories.Learn more: https://www.cruxinvestor.com/companies/isoenergySign up for Crux Investor: https://cruxinvestor.com

Alexis Garcia and Ed Carson walk through Thursday's market action and discuss key stocks to watch in Stock Market Today. Learn more about your ad choices. Visit megaphone.fm/adchoices

While at CIBC's Annual Institutional Investor Conference in Whistler, we had the exciting opportunity to host Grant Isaac of Cameco for this Special Edition COBT. Grant serves as President and Chief Operating Officer of Cameco and has held several roles over his 16-plus years with the company, including EVP & CFO and SVP of Corporate Services. In his current role, he is responsible for all Cameco operations, exploration, and corporate development, as well as the company's commercial and financial strategy. Grant earned a Ph.D. from the London School of Economics and previously served as a business professor at the University of Saskatchewan. We were delighted to sit down with Grant to explore the latest developments in nuclear energy. In our discussion, Grant outlines Cameco's integrated nuclear platform and strategy, with vertical integration as a way to help “build their own demand,” as each reactor build creates 80-100 years of downstream recurring fuel and services demand. We explore how nuclear has shifted from “maybe/what if” to “must do it now,” what drives ordering momentum, and the industry's push to turn nuclear from a project into a product through standardization, sequencing, and simplification. Grant discusses how investors are increasingly underwriting Cameco as a “nuclear super-major” with scarce, strategic assets, and how the Westinghouse acquisition and partnership with Brookfield broadened the shareholder base and improved visibility into future demand. We touch on supply-chain pinch points across mining, conversion, enrichment, and fabrication, the post-Russia fuel-cycle reset, and why uranium is uniquely constrained by geology and can't be “fixed” with industrial policy. Grant explains the Global Laser Enrichment (GLE) project, the role of public-private partnerships in capital-intensive nuclear projects, and Ontario as a positive case study for government involvement. Grant also shares why traditional NPV frameworks tend to undervalue nuclear assets, noting that governments and sponsors instead focus on payback math over 80–100-year asset lives, the significant economic multipliers from large-scale nuclear builds, and the “cluster effects” that attract long-term industry, jobs, and investment, making the case for nuclear as a generational, nation-building infrastructure investment. We also cover evolving investor frameworks and valuation metrics, expectations for consolidation in the nuclear sector, his outlook for 2026, the future of uranium supply, and more. It was an insightful conversation. In other nuclear news, the World Nuclear Association published a World Nuclear Outlook Report on Tuesday, January 20 (linked here), which provides the most comprehensive assessment to date of global nuclear energy development, assessing national targets for nuclear capacity against the global goal to triple nuclear capacity by 2050. We hope you enjoy the discussion with Grant as much as we did. Our best to you all!

Nuclear power and private jets take Tim Bohen's attention on today's Big 3. Tim points to Oklo Inc.'s (OKLO) cooldown as a new base for shares, Cameco's (CCJ) "safer" exposure to the nuclear sector, and Flyexecutive's (FLYX) SpaceX tie as reasons to watch his stock picks. Rick Ducat showcases bearish and bullish trend for all three stocks. ======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about